Vaxcyte, Inc. (PCVX) Stock Price & Analysis

Vaxcyte, Inc. (PCVX) rose 1.19% to USD 46.88 as of June 10, 2026 at 00:52 UTC, according to Nexqual real-time market data.

PCVX last closed at USD 46.33; the session ranged USD 46.1–47.6 on volume of 1,008,607 shares. Market capitalization is $6.77B, with a 52-week range of USD 29.08–65 (NMS). Source: Nexqual, June 10, 2026 at 00:52 UTC.

Key Statistics (as of June 10, 2026 at 00:52 UTC)

Technical Analysis (PCVX)

Nexqual's technical model rates PCVX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:52 UTC.

Analyst Ratings (PCVX)

Wall Street analysts rate PCVX "Strong Buy" based on 9 analysts, with a mean price target of USD 109 (range USD 67–163), per Nexqual as of June 10, 2026 at 00:52 UTC.

Earnings (PCVX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:52 UTC.

Financials & Fundamentals (PCVX)

Source: Nexqual, June 10, 2026 at 00:52 UTC.

Financial Health Score (PCVX)

Nexqual rates Vaxcyte, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:52 UTC.

Ownership (PCVX)

Source: Nexqual, June 10, 2026 at 00:52 UTC.

Leadership (PCVX)

Vaxcyte, Inc. is led by Grant E. Pickering (age 57), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 00:52 UTC.

Major Backers & Investors (PCVX)

Notable institutional backers of Vaxcyte, Inc. include Janus Henderson Group PLC, FMR, LLC, T. Rowe Price, according to Nexqual as of June 10, 2026 at 00:52 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:52 UTC.

From Vaxcyte, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform Our modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, offer several advantages over conventional cell-based protein expression methods, which we believe enable us to generate superior, novel, broader-spectrum and/or more immunogenic vaccines.
• The vaccines to prevent RSV from Pfizer and GSK that were approved by the FDA in May 2023, and from Moderna that was approved by the FDA in May 2024, generated approximately $1.8 billion in global sales in 2025.
• In that study, the OPA responses directed against the polysaccharides of interest for all thirteen of the common strains were lower for PCV20 (Figure 6). 12 Table of Contents 1 IgG Geometric Mean Concentrations post-dose 4 – Prevnar 20 Biologics License Application ("BLA") Clinical Review Memorandum by FDA (STN: 125731/189).
• In contrast, the precision and flexibility of cell-free protein expression, together with our ability to insert nnAAs, allow us to construct our proprietary enhanced protein carrier ("eCRM") with pre-determined conjugation sites.

Partnerships

• In addition, in September 2025, we announced a new agreement with Patheon Manufacturing Services, LLC, part of Thermo Fisher Scientific (collectively, "Thermo Fisher") to provide custom commercial fill-finish capacity for our broad-spectrum PCVs at Thermo Fisher's Greenville, North Carolina facility.
• In October 2023, to complement this plan, we entered into a new commercial manufacturing agreement with Lonza to support the potential global commercialization of our PCV candidates in both the adult and pediatric populations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:52 UTC. This page is informational and not investment advice.